| Lack of methemoglobinemia with flutamide. | |
| | |
MedLine Citation:
|
PMID: 11197580 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To determine whether the nonsteroidal antiandrogenic drug flutamide is a clinically relevant inducer of methemoglobinemia in patients with prostatic cancer. METHODS: Fifty consecutive outpatients with prostatic cancer stage D2 entered the study (age 71.1 +/- 7.3 y). Five patients were lost to follow-up; the remaining 45 patients received the recommended oral dose of flutamide 250 mg three times daily. Total hemoglobin (Hb) and methemoglobin (Met-Hb) concentrations were measured on varying days using an ultraviolet/visible-spectrophotometric method with an intra- and interday variability < 8%. In 12 patients, Met-Hb was analyzed before initiating flutamide therapy and after therapy was begun. RESULTS: On average, 2.6 venous blood samples per patient were analyzed with a mean Met-Hb concentration of 1.9% of total Hb. Mean concentrations of > or = 3% were detected in only six patients (13%). The data from 12 patients evaluated before and after initiating flutamide therapy were without significantly different changes. During the study period, no clinical signs of methemoglobinemia were reported or observed. CONCLUSIONS: This study found no clinically relevant increase of Met-Hb concentrations in elderly patients with prostatic cancer during chronic treatment with flutamide. However, clinicians should be aware of the very rare possibility of flutamide-induced methemoglobinemia. |
| | |
Authors:
|
M Schulz; A Schmoldt; F Donn; H Becker |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: The Annals of pharmacotherapy Volume: 35 ISSN: 1060-0280 ISO Abbreviation: Ann Pharmacother Publication Date: 2001 Jan |
Date Detail:
|
Created Date: 2001-01-25 Completed Date: 2001-03-08 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9203131 Medline TA: Ann Pharmacother Country: United States |
Other Details:
|
Languages: eng Pagination: 21-5 Citation Subset: IM |
Affiliation:
|
Center for Drug Information and Pharmacy Practice, ABDA-Federal Union of German Associations of Pharmacists, Eschborn, Germany. M.Schulz@abda.aponet.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Antineoplastic Agents, Hormonal / adverse effects, therapeutic use* Flutamide / adverse effects, therapeutic use* Humans Male Methemoglobin / drug effects, metabolism Methemoglobinemia / chemically induced* Middle Aged Prostatic Neoplasms / blood, drug therapy*, pathology Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents, Hormonal; 13311-84-7/Flutamide; 9008-37-1/Methemoglobin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Evaluation of outcomes in converting from intravenous ondansetron to oral granisetron: an observatio...
Next Document: Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin.